Related Experiment Video

Updated: Jul 25, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment

Shinichiro Takahashi1

  • 1Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan.

Hematology Reports
|June 27, 2023
PubMed

Insights

Combination therapies targeting kinase pathways show promise for treating acute myeloid leukemia (AML). Combining kinase inhibitors may offer a more effective strategy than single agents for AML treatment.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Aberrant kinase pathway activation is crucial in acute myeloid leukemia (AML) pathogenesis, driving abnormal cell proliferation and differentiation.
  • Targeting kinase activity presents a promising therapeutic strategy for AML.
  • While single-agent kinase inhibitor trials are limited, combination therapies are gaining interest.

Purpose of the Study:

  • To review key kinase pathways for therapeutic targeting in AML.
  • To summarize combination strategies for these pathways.
  • To highlight the potential of combination therapies over monotherapies in AML.

Main Methods:

  • Literature review of kinase pathways and combination strategies in AML.
  • Focus on FLT3, PI3K/AKT/mTOR, CDK, and CHK1 pathways.
  • Analysis of existing clinical trial data and preclinical studies.

Main Results:

  • Combination therapies involving kinase inhibitors demonstrate greater promise than monotherapies.
  • Specific focus on FLT3, PI3K/AKT/mTOR, CDK, and CHK1 pathways reveals potential synergistic effects.
  • Evidence suggests combination approaches are superior to single-agent treatments.

Conclusions:

  • Combination therapies with kinase inhibitors are a more effective therapeutic strategy for AML than single agents.
  • Further development of efficient combination therapies is crucial for advancing AML treatment.
  • Targeting multiple kinase pathways simultaneously holds significant potential for overcoming AML.
Keywords:
acute myeloid leukemiacombinationkinase inhibitorstherapy

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

182
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K